Catalent Cell and Gene Therapy is a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent’s experience in autologous and allogeneic cell therapy complements its industry-leading expertise and commercial success in gene therapy development, manufacturing, and adeno-associated virus (AAV) vector production. Its cell therapy offering includes expertise with a variety of cell types including chimeric antigen receptor T cells (CAR-T). With facilities in the US and Europe and continued new investments, Catalent is dedicated to supporting its customers and their patients. Catalent has produced more than 100 cGMP batches across 60+ clinical and commercial programs.
by Nick Paul Taylor
Adicet Bio has struck a deal to merge with resTORbio, bagging itself a Nasdaq listing to support its pipeline of allogeneic gamma delta CAR-Ts.
by Amirah Al Idrus
With 15 programs, $30 million, and a partnership with UT Southwestern, Taysha Gene Therapies plans to be in the clinic by the end of the year.
by Arlene Weintraub
Two NSCLC patients who received Iovance's personalized cell therapy in an early trial achieved complete responses that have lasted more than a year.
by Ben Adams
Sanofi is culling a Regeneron-partnered med and still looking for partners for two unwanted pipeline candidates.
by Angus Liu
Scientists reversed diabetes in mice by using CRISPR to correct a faulty gene in human-induced pluripotent stem cells and turn them into beta cells.
by Ben Adams
All the attention is currently laser-focused on Gilead’s COVID-19 hopeful remdesivir, but the company itself is still penning deals in cancer.
by Nick Paul Taylor
Sangamo is paying an upfront fee to get Mogrify to apply its direct cell conversion technology to the generation of regulatory T cells.
by Nick Paul Taylor
Bellicum doesn’t expect MD Anderson’s actions to “have a significant impact” on its programs but warned they may prevent study enrollment.
by Amirah Al Idrus
In a deal with $30 million upfront, Novartis and TScan are on the hunt for targets that could lead to new T-cell receptor therapies for solid cancers.
by Arlene Weintraub
Swedish scientists turned skin cell into nerve cells, which helped repair stroke-damaged nerve circuits when implanted in the brains of rat models.